<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS136910</article-id>
<article-id pub-id-type="doi">10.1101/2021.10.12.464114</article-id>
<article-id pub-id-type="archive">PPR407295</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Greaney</surname>
<given-names>Allison J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Starr</surname>
<given-names>Tyler N.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eguia</surname>
<given-names>Rachel T.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Loes</surname>
<given-names>Andrea N.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khan</surname>
<given-names>Khadija</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karim</surname>
<given-names>Farina</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cele</surname>
<given-names>Sandile</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bowen</surname>
<given-names>John E.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Logue</surname>
<given-names>Jennifer K.</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Corti</surname>
<given-names>Davide</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Veesler</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chu</surname>
<given-names>Helen Y.</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sigal</surname>
<given-names>Alex</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bloom</surname>
<given-names>Jesse D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="fn" rid="FN1">#</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center; Seattle, WA 98109, USA</aff>
<aff id="A2">
<label>2</label>Department of Genome Sciences &amp; Medical Scientist Training Program, University of Washington; Seattle, WA 98195, USA</aff>
<aff id="A3">
<label>3</label>Howard Hughes Medical Institute; Chevy Chase, MD 20815, USA</aff>
<aff id="A4">
<label>4</label>Africa Health Research Institute, Durban 4001, South Africa</aff>
<aff id="A5">
<label>5</label>School of Laboratory Medicine and Medical Sciences, University of KwaZulu–Natal, Durban 4001, South Africa</aff>
<aff id="A6">
<label>6</label>Department of Biochemistry, University of Washington, Seattle, WA 98195, USA</aff>
<aff id="A7">
<label>7</label>Division of Allergy and Infectious Diseases, University of Washington; Seattle, WA 98195, USA</aff>
<aff id="A8">
<label>8</label>Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland</aff>
<author-notes>
<corresp id="CR1">
<email>dcorti@vir.bio</email>
</corresp>
<fn id="FN1">
<label>#</label>
<p id="P1">Lead Contact <email>jbloom@fredhutch.org</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>15</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>13</day>
<month>10</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P2">Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it is unknown if antibodies elicited by infection with these variants target the same or different regions of the viral spike as antibodies elicited by earlier viral isolates. Here we compare the specificities of polyclonal antibodies produced by humans infected with early 2020 isolates versus the B.1.351 variant of concern (also known as Beta or 20H/501Y.V2), which contains mutations in multiple key spike epitopes. The serum neutralizing activity of antibodies elicited by infection with both early 2020 viruses and B.1.351 is heavily focused on the spike receptor-binding domain (RBD). However, within the RBD, B.1.351-elicited antibodies are more focused on the “class 3” epitope spanning sites 443 to 452, and neutralization by these antibodies is notably less affected by mutations at residue 484. Our results show that SARS-CoV-2 variants can elicit polyclonal antibodies with different immunodominance hierarchies.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P3">Over the past year, SARS-CoV-2 viral variants have emerged with mutations that alter the antigenicity of spike and erode neutralization of the virus by infection- and vaccine-elicited polyclonal antibodies (<italic>
<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R13">13</xref>
</italic>). While it is well established that many SARS-CoV-2 variants are less susceptible to antibody immunity generated by early 2020 infections, it is unknown if the antibodies elicited by infection with these variants have different specificities and epitope immunodominance hierarchies. For influenza virus, it has been demonstrated that immunodominance of different epitopes changes over time as the virus evolves antigenically (<italic>
<xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R16">16</xref>
</italic>). If a similar phenomenon occurs for SARS-CoV-2, then the sites of important antigenic mutations will change over time.</p>
<p id="P4">Here we address this question by combining serology and deep mutational scanning to compare the specificity of the polyclonal antibody response elicited by infection with early 2020 viruses versus the B.1.351 variant (also referred to as Beta or 20H/501Y.V2). The B.1.351 variant was first detected in Nelson Mandela Bay, South Africa and likely emerged in August 2020 after the country’s first epidemic wave (<italic>
<xref ref-type="bibr" rid="R17">17</xref>
</italic>). B.1.351 was the dominant lineage in South Africa by the end of 2020, although it has subsequently been displaced by the B.1.617.2 (Delta) lineage (<italic>
<xref ref-type="bibr" rid="R18">18</xref>
</italic>). B.1.351 has mutations throughout the spike protein, including at key epitopes in both the RBD and NTD (<italic>
<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R9">9</xref>
</italic>). The B.1.351 variant has among the largest reductions in neutralization by convalescent plasmas of any SARS-CoV-2 variant to date (<italic>
<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R21">21</xref>
</italic>). Additionally, prior work has demonstrated that B.1.351 convalescent plasmas can neutralize early 2020 viruses better than early 2020 plasmas can neutralize B.1.351 viruses (<italic>
<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R22">22</xref>
</italic>), suggesting that there may be a shift in the specificity of the antibody response. Our results described below expand this understanding by showing that while neutralization by B.1.351-elicited plasma antibodies is still heavily focused on the RBD, their site-specificity within the RBD is somewhat shifted compared to antibodies elicited by early 2020 viruses. Specifically, within the RBD, B.1.351-elicited sera is relatively more targeted to the class 3 epitope (in the classification scheme of (<italic>
<xref ref-type="bibr" rid="R23">23</xref>
</italic>)) and relatively less targeted to the class 1 and 2 epitopes.</p>
</sec>
<sec id="S2" sec-type="results">
<title>Results</title>
<sec id="S3">
<title>The B.1.351 SARS-CoV-2 variant lineage has mutations in multiple spike epitopes</title>
<p id="P5">The B.1.351 spike used in our experiments contained the following mutations relative to the Wuhan-Hu-1 strain: D80A, D215G, del242–244, K417N, E484K, N501Y, D614G, and A701V (<xref ref-type="fig" rid="F1">Fig. 1</xref>); note that some B.1.351 viruses also contain L18F. Three of these mutations are in the RBD (K417N, E484K, and N501Y). K417N and E484K strongly disrupt binding of class 1 and class 2 antibodies, respectively (<italic>
<xref ref-type="bibr" rid="R24">24</xref>
</italic>). N501Y is in or proximal to the class 3 epitope, but does not strongly affect the binding or neutralization of polyclonal convalescent or vaccine-elicited antibodies (<italic>
<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R23">23</xref>
</italic>), although it enhances the RBD’s affinity for its receptor, angiotensin converting enzyme 2 (ACE2) (<italic>
<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R26">26</xref>
</italic>).</p>
</sec>
<sec id="S4">
<title>Convalescent plasma samples from individuals infected with B.1.351 or an early 2020 virus</title>
<p id="P6">We obtained plasma samples collected approximately 30 days post-symptom onset (mean 33, range 27–40 days) from 9 individuals infected with SARS-CoV-2 during the “second wave” of COVID-19 in South Africa from late December 2020 through late January 2021 (<xref ref-type="table" rid="T1">Table 1</xref>). During this timeframe, B.1.351 virus accounted for &gt;90% of sequenced infections in the area (<italic>
<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R18">18</xref>
</italic>). None of the individuals had evidence of prior SARS-CoV-2 infection, so we presume these individuals experienced a primary B.1.351 infection.</p>
<p id="P7">To enable comparison of B.1.351-elicited antibodies to those elicited by infection with an early 2020 virus, we reexamined a set of convalescent plasma samples collected approximately 30 days post-symptom onset (mean 32, range 15–61 days) from 17 individuals with symptom onset on or prior to March 15, 2020 in Washington state, USA (<xref ref-type="table" rid="T1">Table 1</xref>) (<italic>
<xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R28">28</xref>
</italic>). At that time, most sequenced viral isolates in Washington state had spike sequences identical to Wuhan-Hu-1, although D614G viruses were also present at a low level (<italic>
<xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R30">30</xref>
</italic>). No other spike mutations were present at appreciable frequencies at that time.</p>
</sec>
<sec id="S5">
<title>Infection with B.1.351 elicits a neutralizing antibody response at least as RBD-focused as early 2020 viruses</title>
<p id="P8">Early 2020 viruses induce a neutralizing antibody response that largely targets the RBD (<italic>
<xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R32">32</xref>
</italic>), although some neutralizing antibodies also bind the NTD (<italic>
<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R33">33</xref>–<xref ref-type="bibr" rid="R35">35</xref>
</italic>). Because B.1.351 has mutations in both the RBD and NTD, it is important to determine if the specificity of the neutralizing antibody response elicited by this virus is similarly RBD-focused.</p>
<p id="P9">We depleted plasmas from B.1.351-infected individuals of B.1.351 RBD-binding antibodies, or performed a mock depletion, and measured neutralization of B.1.351 spike-pseudotyped lentiviral particles (<xref ref-type="fig" rid="F2">Fig. 2A</xref>, <xref ref-type="supplementary-material" rid="SD6">fig. S1</xref>, <xref ref-type="supplementary-material" rid="SD1">data file S1</xref>). The median neutralization titer (NT50) of these plasmas against the B.1.351-spike-pseudotyped lentiviral particles for the mock depletion was 2,459 (range 259–5,081). For 7 out of 9 samples, greater than 90% of neutralizing activity was ablated by removal of RBD-binding antibodies (<xref ref-type="fig" rid="F2">Fig. 2A</xref>).</p>
<p id="P10">We compared these B.1.351 results to previous measurements of the RBD-focused neutralizing activity of plasmas from individuals infected with early 2020 viruses. These prior measurements were made using Wuhan-Hu-1 RBD depletions and D614G spike-pseudotyped lentiviral particles (<italic>
<xref ref-type="bibr" rid="R28">28</xref>
</italic>). The neutralizing activity of the B.1.351 plasmas was at least as RBD-focused as the early 2020 virus plasmas, with most neutralizing activity of most plasmas from both cohorts attributable to RBD-binding antibodies (<xref ref-type="fig" rid="F2">Fig. 2B,C</xref>). There was a slight trend for the neutralizing activity of the B.1.351 plasmas to be more RBD-focused than the early 2020 plasmas, but the difference was not statistically significant (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). One caveat is that all neutralization assays were performed in 293T cells overexpressing ACE2, which tend to emphasize the effect of RBD-binding, ACE2-competitive antibodies more than assays performed on cells with lower levels of ACE2 expression (<italic>
<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R36">36</xref>
</italic>).</p>
</sec>
<sec id="S6">
<title>Complete mapping of mutations in the B.1.351 RBD that reduce binding by polyclonal plasma antibodies elicited by B.1.351 infection</title>
<p id="P11">To determine how mutations within the RBD affect plasma antibody binding, we used a previously described deep mutational scanning approach. Briefly, this approach involves generating comprehensive mutant libraries of the RBD, displaying the mutant RBDs on the surface of yeast, and using fluorescence-activated cell sorting (FACS) and deep sequencing to quantify how mutations impact antibody binding (<italic>
<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R37">37</xref>
</italic>).</p>
<p id="P12">Previously, we have performed such deep mutational scanning using the RBD from the Wuhan-Hu-1 isolate to map mutations that affect binding by polyclonal antibodies elicited by infection or vaccination that involves a RBD identical to that in Wuhan-Hu-1 (<italic>
<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R38">38</xref>
</italic>). However, for the current work we wanted to determine the specificity of antibodies elicited by B.1.351 infection to the B.1.351 RBD. Therefore, we generated new duplicate libraries containing 99.7% (3,807 of 3,819) of the possible single amino-acid mutations in the B.1.351 RBD. We displayed these libraries on the surface of yeast, and measured the effects of mutations on RBD expression and binding to ACE2 (<xref ref-type="supplementary-material" rid="SD6">fig. S2</xref>, <xref ref-type="supplementary-material" rid="SD2">data file S2</xref> (<italic>
<xref ref-type="bibr" rid="R25">25</xref>
</italic>)). We used computational filters based on these measurements as well as a pre-sort of the library for RBDs that bind ACE2 with at least 1% the avidity of the unmutated B.1.351 RBD to filter spurious antibody-escape mutations that were highly deleterious or led to gross unfolding of the RBD.</p>
<p id="P13">We then measured how all the single RBD mutations affected the binding of polyclonal antibodies in the B.1.351 convalescent plasmas to the B.1.351 RBD. To do this, we incubated the yeast-displayed B.1.351 libraries with each plasma and used fluorescence-activated cell sorting (FACS) to enrich for RBD mutants with reduced antibody binding (<xref ref-type="supplementary-material" rid="SD6">fig. S3A-C</xref>). We deep sequenced the pre- and post-enrichment populations to quantify each mutation’s “escape fraction”. These escape fractions range from 0 (no cells with the mutation in the escape bin) to 1 (all cells with the mutation in the plasma-escape bin) (<xref ref-type="supplementary-material" rid="SD3">data file S3</xref>). The escape fractions measured for independent biological replicate libraries were well-correlated (<xref ref-type="supplementary-material" rid="SD6">fig. S3D</xref>), and in the sections below we report the average across the two replicate libraries. We represent the escape maps as logo plots, where the height of each letter is proportional to its escape fraction (<xref ref-type="supplementary-material" rid="SD6">fig. S3A</xref>).</p>
<p id="P14">
<italic>B.1.351-elicited antibodies focus on different epitopes than early 2020 convalescent samples</italic> We examined the sites and epitopes to which mutations had the greatest effect on antibody binding. We use the Barnes, et al. (<italic>
<xref ref-type="bibr" rid="R23">23</xref>
</italic>) antibody epitope classification scheme, in which there are antibody classes 1 through 4 (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). The class 1, 2, and 3 antibodies are often potently neutralizing, while the class 4 antibodies are usually less potently neutralizing <italic>in vitro</italic> (<italic>
<xref ref-type="bibr" rid="R31">31</xref>–<xref ref-type="bibr" rid="R33">33</xref>, <xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R40">40</xref>
</italic>). Relative to Wuhan-Hu-1, B.1.351 contains mutations in or proximal to the class 1, 2, and 3 epitopes (K417N, E484K, and N501Y, respectively) (<xref ref-type="fig" rid="F3">Fig. 3A</xref>), although the N501Y mutation has little effect on polyclonal convalescent antibody binding or neutralization for Wuhan-Hu-1-like viruses (<italic>
<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R41">41</xref>
</italic>).</p>
<p id="P15">For the B.1.351 plasmas, in 4 of 9 cases, mutations to site 484 within the class 2 epitope had the largest effects on antibody binding and the K484E reversion mutation had little effect (<xref ref-type="fig" rid="F3">Fig. 3B</xref>, <xref ref-type="supplementary-material" rid="SD3">data file S3</xref>). In 3 of 9 cases, mutations to the class 3 epitope (sites 443–450, 498–501, shown in cyan) and the class 2 site 484 had comparably large effects on antibody binding. In two cases, no mutation had a particularly large effect on binding. Mutations to the class 1 and 4 antibody epitopes did not have large effects on plasma binding.</p>
<p id="P16">There are clear differences in the RBD epitope targeting of the B.1.351 plasmas versus previously characterized plasmas from a cohort of individuals (n=11) infected with early 2020 viruses in Washington state, USA (<italic>
<xref ref-type="bibr" rid="R28">28</xref>
</italic>). These 11 samples are a subset of the 17 whose RBD-targeting neutralizing activity is described above (<xref ref-type="fig" rid="F2">Fig 2B,C</xref>). Specifically, binding of the early 2020 plasmas were most affected by mutations to the class 1 and 2 epitopes, with mutations to sites 456, 486, and 484 having some of the largest effects on binding to the RBD (<xref ref-type="fig" rid="F4">Fig. 4</xref>, <xref ref-type="supplementary-material" rid="SD6">fig. S4</xref>, <xref ref-type="supplementary-material" rid="SD4">data file S4</xref>), although mutation to site 456 have little effect on neutralization <italic>in vitro</italic> reflecting the common hyperfocusing of neutralizing antibody responses (<italic>
<xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R38">38</xref>
</italic>). While the B.1.351 plasmas were also strongly affected by mutations to the class 2 epitope and site 484, mutations to the class 1 epitope had little effect. Moreover, while both groups of plasmas are affected by class 3 epitope mutations, the relative importance of class 3 mutations is greater for the B.1.351 plasmas (<xref ref-type="fig" rid="F4">Fig. 4A,B</xref>).</p>
</sec>
<sec id="S7">
<title>Class 3 epitope mutations have a larger effect on neutralization for B.1.351 plasmas, while mutations at the class 2 site 484 have a larger effect for early 2020 plasmas</title>
<p id="P17">To test if the differences in plasma antibody binding specificity described above lead to different effects of mutations on neutralization, we performed neutralization assays on key mutants using spike-pseudotyped lentiviral particles. For these experiments, we chose the eight B.1.351 samples with the highest neutralizing potency (there was not enough residual sample volume to perform neutralization assays with the lowest-potency sample). We also chose four early 2020 samples with substantial RBD-focused neutralizing activity and with antibody-binding escape maps representative of the early 2020 cohort as a whole (<xref ref-type="supplementary-material" rid="SD6">fig. S4</xref>). In all assays, we tested neutralization by B.1.351 and early 2020 plasmas against point mutants in the homologous B.1.351 or D614G spikes.</p>
<p id="P18">Mutations to site 484 had strikingly different effects on neutralization by B.1.351 versus early 2020 plasmas. For the early 2020 plasmas, both E484K/Q mutations, as well as the K417N-E484K-N501Y triple mutation, reduced neutralization by &gt;10-fold, which is comparable to the reduction caused by removing all RBD-binding antibodies from the plasmas (<xref ref-type="fig" rid="F5">Fig. 5</xref>). Therefore, the neutralizing activity of early 2020 plasmas is often highly focused on site 484, as has been described previously (<italic>
<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R41">41</xref>–<xref ref-type="bibr" rid="R44">44</xref>
</italic>). In contrast, mutations to site 484 had much smaller effects on neutralization by B.1.351 plasmas. The K484E reversion had little effect on neutralization by B.1.351 plasmas, which was striking given the large effect of E484K on early 2020 plasma neutralization. While the K484Q mutation had the largest effect on B.1.351 plasmas of any of the single mutations we tested (geometric mean of 3.0-fold change), the effect was smaller than that for the early 2020 plasmas (geometric mean of 18.3-fold change).</p>
<p id="P19">The class 3 epitope was a slightly more important target of neutralization for the B.1.351 plasmas than for early 2020 plasmas, consistent with the deep mutational scanning escape maps. The G446V mutation to the class 3 epitope had a slightly larger, but still modest, effect on neutralization for the B.1.351 plasmas than for most of the early 2020 plasmas (<xref ref-type="fig" rid="F5">Fig. 5</xref>, <xref ref-type="supplementary-material" rid="SD6">fig. S5</xref>). No tested mutation, nor the 417-484-501 triple mutant, reduced neutralization by the B.1.351 plasmas as much as removing all RBD-binding antibodies (<xref ref-type="fig" rid="F5">Fig. 5</xref>), a result in stark contrast to that observed for the early 2020 plasmas.</p>
</sec>
</sec>
<sec id="S8" sec-type="discussion">
<title>Discussion</title>
<p id="P20">We found that a SARS-CoV-2 variant induces antibody responses with different immunodominance hierarchies than early SARS-CoV-2 viral isolates. Changes in immunodominance hierarchies over time and asymmetric antigenic drift have also been observed for influenza virus (<italic>
<xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R16">16</xref>, <xref ref-type="bibr" rid="R45">45</xref>
</italic>). Such changes can have important consequences, as they can contribute to individuals with different exposure histories having different susceptibilities to viral mutants (<italic>
<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R47">47</xref>
</italic>). Although the changes in immunodominance we have observed here are relatively modest, they could become larger as the virus continues to evolve and different individuals accumulate increasingly disparate exposure histories through infection and vaccination (<italic>
<xref ref-type="bibr" rid="R48">48</xref>, <xref ref-type="bibr" rid="R49">49</xref>
</italic>).</p>
<p id="P21">We suggest several speculative hypotheses about several reasons why B.1.351 might elicit different hierarchies of antibodies. Although the B.1.351 spike protein has multiple mutations in key antigenic sites in the RBD and NTD (<italic>
<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>
</italic>), the neutralizing antibody response elicited by B.1.351 infection is at least as RBD-focused as for early 2020 infections, suggesting that none of the RBD mutations have reduced the antigenicity of that spike subdomain. But within the RBD, site 484 is less immunodominant for B.1.351-elicited plasmas. Infection with early 2020 viruses frequently leads to the development of neutralizing class 2 antibodies that target an epitope containing site 484 (<italic>
<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R42">42</xref>, <xref ref-type="bibr" rid="R50">50</xref>, <xref ref-type="bibr" rid="R51">51</xref>
</italic>), and are derived from common antibody germline genes (e.g., IGHV3-53/66, IGHV3-30, IGHV1-2 (<italic>
<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R52">52</xref>, <xref ref-type="bibr" rid="R53">53</xref>
</italic>). We speculate that viruses containing K484 rather than E484 (such as B.1.351) might less readily elicit such neutralizing antibodies (<italic>
<xref ref-type="bibr" rid="R54">54</xref>
</italic>), or might elicit antibodies that draw less of their binding energy from site 484. Furthermore, if the class 2 epitope (containing site 484) is less immunogenic in B.1.351, that could lead to relatively stronger targeting of the class 3 epitope for B.1.351-elicited sera. Note that such phenomena could be human-specific, since the class 2 epitope containing site 484 is not as immunodominant in other species with different germline antibody genes (i.e., rhesus macaques) (<italic>
<xref ref-type="bibr" rid="R55">55</xref>
</italic>).</p>
<p id="P22">Changing immunodominance hierarchies could explain previous reports that polyclonal antibodies elicited by infection with different SARS-CoV-2 variants can have differing neutralizing breadths and specificities (<italic>
<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R56">56</xref>–<xref ref-type="bibr" rid="R58">58</xref>
</italic>). For instance, prior studies of individuals infected with B.1.351 demonstrated that the convalescent plasmas from B.1.351-infected individuals neutralized early 2020 viruses better than early 2020 convalescent plasmas neutralized B.1.351 viruses (<italic>
<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R22">22</xref>
</italic>). Our results help mechanistically explain this finding by showing that one of the key epitopes that differs between early 2020 viruses and B.1.351 (the class 2 epitope centered on site 484) is more immunodominant for early 2020 infections. Such changes in immunodominance hierarchies could also explain recent results suggesting that polyclonal antibodies elicited by B.1.351 infection are less effective at neutralizing the Delta (B.1.617.2) variant than antibodies elicited by early 2020 viruses (<italic>
<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R59">59</xref>
</italic>).</p>
<p id="P23">Our study has several limitations. The cohorts of individuals infected with early 2020 and B.1.351 viruses are small, and are geographically and temporally distinct. Nevertheless, the two cohorts are relatively well-matched with respect to age, sex, and days-post symptom onset of sample collection (<xref ref-type="table" rid="T1">Table 1</xref>) and assays were performed under comparable conditions. Our deep mutational scanning measured binding to yeast-displayed RBD, which may not capture all relevant features of full-length spike in the context of virus. Finally, our neutralization assays used pseudotyped lentiviral particles and ACE2-overexpressing cells, and some recent works suggest that the relative importance of different spike epitopes for neutralization can depend on the viral system and target cell line used (<italic>
<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R60">60</xref>
</italic>).</p>
<p id="P24">Although the B.1.351 variant has now been displaced by the Delta variant, our results illustrate the need to understand immunity elicited by different SARS-CoV-2 variants. As population immunity due to infection or vaccination increases, preexisting immunity is becoming an increasingly important driver of SARS-CoV-2 evolution (<italic>
<xref ref-type="bibr" rid="R61">61</xref>
</italic>), as has shown to be the case for seasonal coronaviruses (<italic>
<xref ref-type="bibr" rid="R62">62</xref>, <xref ref-type="bibr" rid="R63">63</xref>
</italic>). Moreover, as individuals begin to accumulate more complex SARS-CoV-2 immune histories due to multiple infections and/or vaccinations, the effects of immune imprinting or original antigenic sin (<italic>
<xref ref-type="bibr" rid="R64">64</xref>, <xref ref-type="bibr" rid="R65">65</xref>
</italic>) may start to interact with the variant-specific immunodominance hierarchies we have described to create increasingly diverse antibody specificities in the human population.</p>
</sec>
<sec id="S9" sec-type="methods">
<title>Methods</title>
<sec id="S10">
<title>Description of cohort and ethics statement</title>
<p id="P25">Samples were collected from participants enrolled in a prospective cohort study approved by the Biomedical Research Ethics Committee (BREC) at the University of KwaZulu–Natal (reference BREC/00001275/2020). Written informed consent was obtained from each participant. The mean age was 54 years (median 53; range 26–78 years). Four were males and 5 were females. All participants had symptomatic SARS-CoV-2 infection and a positive SARS-CoV-2 qPCR from a swab of the upper respiratory tract, and all participants required hospitalization. All 9 participants were HIV-negative. None of the participants had evidence of prior SARS-CoV-2 infection. Blood was sampled approximately 30 days post-symptom onset (mean 32.9, range 27–40 days) from 9 individuals infected with SARS-CoV-2 during the “second wave” of infections in South Africa from late December 2020 through late January 2021, when the B.1.351 virus was detected in &gt;90% of sequenced infections in the area (<italic>
<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R18">18</xref>
</italic>). B.1.351 infection was corroborated by the experimental findings in this paper that all plasmas bound to B.1.351 spike and RBD, had reduced binding to DMS library variants with mutations to site 484, and better neutralized B.1.351 spike-pseudotyped lentiviral particles relative to D614G particles. All participant samples had detectable antibody binding and neutralizing titers against B.1.351 SARS-CoV-2 spike.</p>
<p id="P26">Early-2020 convalescent plasma samples were previously described (<italic>
<xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R28">28</xref>
</italic>) and collected as part of a prospective longitudinal cohort study of individuals with SARS-CoV-2 infection in Seattle, WA, between February and July 2020. The plasma samples from 17 individuals were examined here (8 of 17 females; age range 23 to 76 years, mean 51.6 years, median 56 years). These samples were collected approximately 30 days post-symptom onset (mean 31.6 days, median 29 days, min 15 days, max 61 days). Five cases were hospitalized, 2 were asymptomatic, and the remainder were symptomatic non-hospitalized. The neutralization activity of plasma samples before and after depletion of RBD-binding antibodies in <xref ref-type="fig" rid="F2">Fig. 2</xref> and RBD binding-escape maps in <xref ref-type="supplementary-material" rid="SD6">fig. S4</xref> were previously reported (<italic>
<xref ref-type="bibr" rid="R28">28</xref>
</italic>), but neutralization assays for all 30-days post-symptom onset plasmas in <xref ref-type="fig" rid="F5">Fig. 5</xref>, <xref ref-type="supplementary-material" rid="SD6">fig. S5</xref> were newly performed in this study. The neutralization assays on the 100-day early 2020 samples in <xref ref-type="supplementary-material" rid="SD6">fig. S5</xref> were previously reported (<italic>
<xref ref-type="bibr" rid="R38">38</xref>
</italic>). This work was approved by the University of Washington Institutional Review Board.</p>
</sec>
<sec id="S11">
<title>Plasma separation from whole blood</title>
<p id="P27">Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 rcf for 10 min and stored at −80 °C. Aliquots of plasma samples were heat-inactivated at 56 °C for 30 min and clarified by centrifugation at 10,000 rcf for 5 min, after which the clear middle layer was used for experiments. Inactivated plasma was stored in single-use aliquots to prevent freeze-thaw cycles.</p>
</sec>
<sec id="S12">
<title>Construction of B.1.351 RBD yeast-displayed DMS library</title>
<p id="P28">Duplicate single-mutant site-saturation variant libraries were designed in the background of the spike receptor binding domain (RBD) from SARS-CoV-2 B.1.351 (identical to that from Wuhan-Hu-1, Genbank accession number MN908947, residues N331-T531, with the addition of the following amino-acid substitutions: K417N, E484K, N501Y), and produced by Twist Bioscience. The Genbank map of the plasmid encoding the unmutated SARS-CoV-2 B.1.351 RBD in the yeast-display vector is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/data/plasmid_maps/3021_pETcon-SA_RS-CoV-2-RBD_K417N_E484K_N501Y.gb">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/data/plasmid_maps/3021_pETcon-SA_RS-CoV-2-RBD_K417N_E484K_N501Y.gb</ext-link>. The site-saturation variant libraries were delivered as double-stranded DNA fragments by Twist Bioscience. The final unmutated DNA sequence delivered is: <disp-quote id="Q1">
<p id="P29">
<underline>tctgcaggctagtggtggag</underline>sgaggctctggtggaggcggCCgcggaggcggagggtcggctagccatatgAATATCACGAACCTTTGTCCTTTCGGTGAGGTCTTCAATGCTACTAGATTCGCATCCGTGTATGCATGGAATAGAAAGAGAATTAGTAATTGTGTAGCGGACTACTCTGTACTTTATAACTCCGCCTCCTTCTCCACATTCAAGTGTTACGGTGTATCTCCCACCAAGTTGAATGATCTATGCTTTACAAACGTTTACGCCGATAGTTTCGTAATTAGAGGCGATGAAGTGCGTCAGATCGCACCAGGCCAGACGGGCAACATAGCAGACTATAATTATAAGCTGCCTGATGACTTCACCGGCTGTGTGATAGCTTGGAACTCAAATAATCTAGATTCCAAGGTGGGAGGCAATTACAATTATTTGTACCGTCTGTTCCGTAAAAGCAATTTGAAACCATTTGAAAGAGACATTAGCACTGAAATTTATCAAGCAGGGTCCACCCCGTGCAACGGCGTAAAGGGCTTTAACTGTTATTTCCCATTACAGTCTTATGGTTTCCAACCTACGTACGGAGTCGGGTATCAGCCGTACAGGGTTGTGGTTCTTTCATTTGAACTGCTGCACGCGCCCGCAACCGTATGCGGGCCGAAGAAATCAACGctcgaggggggcggttccgaacaaaagcttatttctgaagaggacttgtaatagagatctgataacaacagtgtagatgtaacaaaatcgactttgttcccactgtacttttagctcgtacaaaatacaatatacttttcatttctccgtaaacaacatgttttcccatgtaatatccttttctatttttcgttccgttaccaactttacacatactttatatagctattcacttctatacactaaaaaactaagacaattttaattttgctgcctgccatatttcaatttgttataaattcctataatttatcctattagtagctaaaaaaagat<underline>gaatgtgaatcgaatcctaagag aatt</underline>
</p>
</disp-quote>
</p>
<p id="P30">This sequence has 5’ and 3’ flanking sequences that are unmutated in the variant libraries (lower case). The uppercase portion is the RBD coding sequence, amino acids N331–T531 (Wuhan-Hu-1 spike numbering). The libraries were designed to contain all 19 amino acids at each site in the RBD, without stop codons, with no more than one amino-acid mutation per variant. The variant gene fragments were PCR-amplified with these primers: 5’-tctgcaggctagtggtggag-3’ and 5’-agatcggaagagcgtcgtgtagggaaagagtgtagatctcggtggtcgccgtatcattaattctcttaggattcgattcacattc-3’. (primer-binding regions underlined in the sequence above). A second round of PCR was performed using the same forward primer (5’-tctgcaggctagtggtggag-3’) and the reverse primer 5’-ccagtgaattgtaatacgactcactatagggcgaattggagctcgcggccgcnnnnnnnnnnnnnnnnagatcggaagagcgtcgtgtag-3’ to append the Nx16 barcodes and add the overlapping sequences to clone into the recipient vector backbone as described in (<italic>
<xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R66">66</xref>
</italic>).</p>
<p id="P31">Failed positions in the Twist-delivered library (sites 362, 501, and 524 in Wuhan-Hu-1 numbering) were mutagenized in-house using a PCR-based method with NNS degenerate primers and cloned into the unmutated wildtype backbone plasmid using NEB HiFi assembly, exactly as described in (<italic>
<xref ref-type="bibr" rid="R66">66</xref>
</italic>). These were then PCR-amplified using the same 5’-tctgcaggctagtggtggag-3’ and 5’-ccagtgaattgtaatacgactcactatagggcgaattggagctcgcggccgcnnnnnnnnnnnnnnnnagatcggaagagcgtcgtgtag-3’ primers to pool with the barcoded Twist library gene fragments.</p>
<p id="P32">The barcoded variant gene fragments were cloned in bulk into the NotI/SacI-digested unmutated wildtype plasmid, as described in (<italic>
<xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R66">66</xref>
</italic>). The Genbank plasmid map for the fully assembled, barcoded B.1.351 RBD libraries (with the unmutated B.1.351 RBD sequence) is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/data/plasmid_maps/pETcon-SARS-Co_V-2-RBD-B1351_lib-assembled.gb">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/data/plasmid_maps/pETcon-SARS-Co_V-2-RBD-B1351_lib-assembled.gb</ext-link>. The pooled, barcoded mutant libraries were electroporated into <italic>E. coli</italic> (NEB 10-beta electrocompetent cells, New England BioLabs C3020K) and plated at a target bottleneck of 50,000 variants per duplicate library, corresponding to &gt;10 barcodes per mutant within each library. Colonies from bottlenecked transformation plates were scraped and plasmid purified. Plasmid libraries (10 μg plasmid per replicate library) were transformed into the AWY101 yeast strain (<italic>
<xref ref-type="bibr" rid="R67">67</xref>
</italic>) according to the protocol of Gietz and Schiestl (<italic>
<xref ref-type="bibr" rid="R68">68</xref>
</italic>).</p>
</sec>
<sec id="S13">
<title>PacBio sequencing to link variant mutations and barcodes</title>
<p id="P33">As described by Starr et al. (<italic>
<xref ref-type="bibr" rid="R25">25</xref>
</italic>), PacBio sequencing was used to generate long sequence reads spanning the Nx16 barcode and RBD coding sequence. PacBio sequencing amplicons were prepared from library plasmid pools via NotI digestion, gel purification, and Ampure XP bead clean-up. Sample-specific barcodes and SMRTbells were ligated using the HiFi Express v2 kit. The multiplexed libraries were sequenced on a PacBio Sequel II with a 15-hour movie collection time. Demultiplexed PacBio HiFi circular consensus sequences (CCSs) were generated using the SMRT Link GUI, version 10.1.0.119588. HiFi reads are CCSs with &gt;=3 full passes and a mean quality score Q &gt;=20. The resulting CCSs are available on the NCBI Sequence Read Archive, BioProject PRJNA770094, BioSample SAMN22208699.</p>
<p id="P34">HiFi reads were processed using alignparse (version 0.2.6) (<italic>
<xref ref-type="bibr" rid="R69">69</xref>
</italic>) to determine each variant’s mutations and the associated Nx16 barcode sequence, requiring no more than 45 nucleotide mutations from the intended target sequence, an expected 16-nt length barcode sequence, and no more than 4 mismatches across the sequenced portions of the vector backbone. Attribution of barcodes to library variants determined that the libraries contained 3,807 of the 3,819 possible single amino-acid mutations to the B.1.351 RBD. Approximately 26% of barcodes in the duplicate libraries corresponded to wildtype B.1.351 RBD (<xref ref-type="supplementary-material" rid="SD6">Fig. S2A</xref>). The libraries were designed to contain only wildtype and 1-amino acid mutations, but some multiple mutations and stop codons were stochastically introduced during the library generation process. These mutations were excluded from downstream analysis of the effects of mutations on ACE2 binding, RBD expression, and plasma antibody binding, except when used in quality control checks (i.e., that most variants containing premature stop codons should not be expressed on the yeast cell surface and thus should have very low expression scores).</p>
</sec>
<sec id="S14">
<title>Determining the effects of mutations on RBD expression and ACE2 binding to filter the library for functional variants</title>
<p id="P35">The effects of each mutation on RBD expression on the surface of yeast and on ACE2 binding were measured essentially as described previously for the Wuhan-Hu-1 RBD (<italic>
<xref ref-type="bibr" rid="R25">25</xref>
</italic>). Specifically, each biological replicate library was grown overnight at 30°C in 45mL SD-CAA media (6.7g/L Yeast Nitrogen Base, 5.0g/L Casamino acids, 1.065 g/L MES acid, and 2% w/v dextrose) at an initial OD600 of 0.4. To induce RBD surface expression, yeast were back-diluted in SG-CAA+0.1%D (2% w/v galactose supplemented with 0.1% dextrose) induction media at 0.67 OD600 and incubated at room temperature for 16–18 hours with mild agitation. For RBD expression experiments, 45 OD units of yeast were labeled in 1:100 diluted chicken-anti-Myc-FITC antibody (Immunology Consultants CMYC45F) to detect the RBD’s C-terminal Myc tag. For ACE2-binding experiments, 12 OD units of yeast were incubated overnight at room temperature with monomeric biotinylated ACE2 (ACROBiosystems AC2-H82E8) across a concentration range of 10<sup>-13</sup> M to 10<sup>-6</sup> M at 1-log intervals. Labeling volumes were increased at low ACE2 concentration to limit ligand depletion effects. Cells were then labeled with 1:100 diluted Myc-FITC to detect RBD expression and 1:200 Streptavidin-PE (Invitrogen S866) to detect binding of biotinylated ACE2.</p>
<p id="P36">Cells were processed on a BD FACSAria II and sorted into four bins from low to high RBD expression (measured by myc-FITC staining) or ACE2 binding (measured by streptavidin-PE fluorescence). The RBD expression sort bins were set such that bin 1 would capture 99% of unstained cells, and the remaining 3 bins divide the remainder of each mutant RBD library into equal tertiles. For ACE2 binding, bin 1 captured 95% of cells expressing unmutated RBD incubated with no ACE2 (0 M), and bin 4 captured 95% of cells expressing unmutated RBD incubated with a saturating amount of ACE2 (10<sup>-6</sup> M). Bins 2 and 3 equally divided the distance between the bin 1 upper and bin 4 lower fluorescence boundaries on a log scale. The frequency of each variant in each bin was determined by Illumina sequencing of RBD variant barcodes.</p>
<p id="P37">The effects of each mutation on RBD expression and ACE2 binding were determined as described in (<italic>
<xref ref-type="bibr" rid="R25">25</xref>
</italic>). RBD mutant expression and ACE2 binding scores were calculated according to the equations in (<italic>
<xref ref-type="bibr" rid="R25">25</xref>
</italic>). For ACE2 binding, a score of –1.0 corresponds to a 10-fold loss in affinity (K<sub>d</sub>) compared to the wildtype RBD. For RBD expression, a score of –1.0 corresponds to a 10-fold reduction in mean RBD-myc-FITC fluorescence intensity. These measurements were used to computationally filter library variants that were highly deleterious for RBD expression or ACE2 binding and would likely represent spurious antibody-escape mutations (see below for details). The ACE2 binding and RBD expression scores for the single amino-acid mutations in the B.1.351 RBD are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/data/final_variant_scores.csv">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/data/final_variant_scores.csv</ext-link>.</p>
<p id="P38">As previously described, prior to performing the antibody-escape experiments, the yeast libraries were pre-sorted for RBD expression and binding to dimeric ACE2 (ACROBiosystems AC2-H82E6) to eliminate RBD variants that are completely misfolded or non-functional, such as those lacking modest ACE2 binding affinity (<italic>
<xref ref-type="bibr" rid="R37">37</xref>
</italic>). Specifically, unmutated B.1.351 RBD and each RBD mutant library were incubated with dimeric ACE2 at 10<sup>-8</sup> M (a saturating concentration of ACE2 for unmutated B.1.351 RBD). A FACS selection gate was set to capture 98% of cells expressing unmutated B.1.351 RBD that were incubated with 10<sup>-10</sup> M ACE2, to purge the mutant libraries of highly deleterious mutations (i.e., those that have &lt;1% the affinity of unmutated B.1.351 RBD). These pre-sorted yeast libraries containing RBD variants with at least nominal expression and ACE2 binding were used in downstream antibody-escape experiments (see below).</p>
</sec>
<sec id="S15">
<title>Depleting plasma of nonspecific yeast-binding antibodies prior to antibody-escape experiments</title>
<p id="P39">Prior to the yeast-display deep mutational scanning, plasma samples were twice-depleted of nonspecific yeast-binding antibodies. AWY101 yeast containing a negative control (containing an empty vector pETcon plasmid) were grown overnight at 30°C in galactose-containing media. Then, up to 50 microliters of plasma samples were incubated, rotating, with 40 OD units of the yeast for 2 hours at room temperature in a total volume of 1mL. The yeast cells were pelleted by centrifugation, and the supernatant was transferred to an additional 40 OD units of yeast cells, and the incubation was repeated overnight at 4°C. Before beginning the plasma-escape mapping experiments, the negative control yeast were pelleted by centrifugation and the supernatant (containing serum antibodies but not negative control yeast or yeast-binding antibodies) was used in plasma-escape mapping.</p>
</sec>
<sec id="S16">
<title>FACS sorting of yeast libraries to select B.1.351 mutants with reduced binding by polyclonal plasmas from B. 1.351-convalescent individuals</title>
<p id="P40">Plasma mapping experiments were performed in biological duplicate using the independent mutant RBD libraries, similarly to as previously described for monoclonal antibodies (<italic>
<xref ref-type="bibr" rid="R37">37</xref>
</italic>) and polyclonal plasma samples (<italic>
<xref ref-type="bibr" rid="R28">28</xref>
</italic>). Mutant yeast libraries induced to express RBD were washed and incubated with plasma at a range of dilutions for 1 hour at room temperature with gentle agitation. For each plasma, we chose a sub-saturating dilution such that the amount of fluorescent signal due to plasma antibody binding to RBD was approximately equal across samples. The exact dilution used for each plasma is given in <xref ref-type="supplementary-material" rid="SD6">fig. S3</xref>. After the plasma incubations, the libraries were secondarily labeled for 1 hour with 1:100 fluorescein isothiocyanate-conjugated anti-MYC antibody (Immunology Consultants Lab, CYMC-45F) to label for RBD expression and 1:200 Alexa Fluor-647-conjugated goat anti-human-IgA+IgG+IgM (Jackson ImmunoResearch 109-605-064) to label for bound plasma antibodies. A flow cytometric selection gate was drawn to capture 3–6% of the RBD mutants with the lowest amount of plasma binding for their degree of RBD expression (<xref ref-type="supplementary-material" rid="SD6">fig. S3</xref>). For each sample, approximately 10 million RBD<sup>+</sup> cells (range 10<sup>7</sup> to 1.5 x 10<sup>7</sup> cells) were processed on the BD FACSAria II cell sorter, with between 4 x 10<sup>5</sup> and 2 x 10<sup>6</sup> plasma-escaped cells collected per sample. Antibody-escaped cells were grown overnight in synthetic defined medium with casamino acids (6.7g/L Yeast Nitrogen Base, 5.0g/L Casamino acids, 1.065 g/L MES acid, and 2% w/v dextrose +100 U/mL penicillin +100 μg/mL streptomycin) to expand cells prior to plasmid extraction.</p>
</sec>
<sec id="S17">
<title>DNA extraction and Illumina sequencing</title>
<p id="P41">Plasmid samples were prepared from 30 optical density (OD) units (1.6e8 colony forming units (cfus)) of pre-selection yeast populations and approximately 5 OD units (~3.2e7 cfus) of overnight cultures of plasma-escaped cells (Zymoprep Yeast Plasmid Miniprep II) as previously described (<italic>
<xref ref-type="bibr" rid="R37">37</xref>
</italic>). The 16-nucleotide barcode sequences identifying each RBD variant were amplified by polymerase chain reaction (PCR) and prepared for Illumina sequencing as described in (<italic>
<xref ref-type="bibr" rid="R25">25</xref>
</italic>). Specifically, a primer with the sequence 5’-AATGATACGGCGACCACCGAGA-3’ was used to anneal to the Illumina P5 adaptor sequence, and the PerkinElmer NextFlex DNA Barcode adaptor primers with the sequence 5’-CAAGCAGAAGACGGCATACGAGATxxxxxxxxGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT -3’ (where xxxxxxxx indicates the sample index sequence) were used to anneal to the Illumina P7 adaptor sequence and append sample indexes for sample multiplexing. Barcodes were sequenced on an Illumina HiSeq 2500 with 50 bp single-end reads. To minimize noise from inadequate sequencing coverage, we ensured that each antibody-escape sample had at least 2.5x as many post-filtering sequencing counts as FACS-selected cells, and reference populations had at least 2.5e7 post-filtering sequencing counts.</p>
</sec>
<sec id="S18">
<title>Analysis of deep sequencing data to compute each mutation’s escape fraction</title>
<p id="P42">Escape fractions were computed as described in (<italic>
<xref ref-type="bibr" rid="R37">37</xref>
</italic>), with minor modifications as noted below. We used the dms_variants package (<ext-link ext-link-type="uri" xlink:href="https://jbloomlab.github.io/dms_variants/">https://jbloomlab.github.io/dms_variants/</ext-link>, version 0.8.10) to process Illumina sequences into counts of each barcoded RBD variant in each pre-selection and antibody-escape population. For each plasma selection, we computed the escape fraction for each barcoded variant using the deep sequencing counts for each variant in the original and plasma-escape populations and the total fraction of the library that escaped antibody binding via the formula provided in (<italic>
<xref ref-type="bibr" rid="R37">37</xref>
</italic>). These escape fractions represent the estimated fraction of cells expressing that specific variant that falls in the escape bin, such that a value of 0 means the variant is always bound by plasma and a value of 1 means that it always escapes plasma binding.</p>
<p id="P43">We then applied a computational filter to remove variants with &gt;1 amino-acid mutation, low sequencing counts, or highly deleterious mutations that might cause antibody escape simply by leading to poor expression of properly folded RBD on the yeast cell surface (<italic>
<xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R37">37</xref>
</italic>). Specifically, we removed variants that had ACE2 binding scores &lt; –3.0 or expression scores &lt; –1.0, after calculating mutation-level deep mutational scanning scores for this library as in (<italic>
<xref ref-type="bibr" rid="R25">25</xref>
</italic>). An ACE2 binding score threshold of –3.0 retained 99.4% and an RBD expression score threshold of –1.0 retained 93.8% of all RBD mutations observed &gt;=50x in GISAID as of Aug. 1, 2021 (<xref ref-type="supplementary-material" rid="SD6">fig. S2C</xref>).</p>
<p id="P44">We also removed all mutations where the wildtype residue was a cysteine. There were 2,014 out of the possible 3,653 mutations to non-disulfide bond residues in the RBD that passed these computational filters.</p>
<p id="P45">The reported antibody-escape scores throughout the paper are the average across the libraries; these scores are also in <xref ref-type="supplementary-material" rid="SD3">data file S3</xref>. Correlations in final single-mutant escape scores are shown in <xref ref-type="supplementary-material" rid="SD6">fig. S3D</xref>.</p>
<p id="P46">For plotting and analyses that required identifying RBD sites of strong escape, we considered a site to mediate strong escape if the total escape (sum of mutation-level escape fractions) for that site exceeded the median across sites by &gt;5-fold, and was at least 5% of the maximum for any site. Full documentation of the computational analysis is at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351</ext-link>.</p>
</sec>
<sec id="S19">
<title>Differences between composition and analysis of B.1.351 RBD libraries and Wuhan-Hu-1 libraries</title>
<p id="P47">Importantly, because the B.1.351 libraries were generated using a different method than the Wuhan-Hu-1 RBD libraries, which is fully described in (<italic>
<xref ref-type="bibr" rid="R25">25</xref>
</italic>), the analysis of deep sequencing data to compute each mutation’s escape fraction is also different. The newly generated B.1.351 libraries were ordered from Twist Bioscience to have one amino-acid mutation per variant, whereas the Wuhan-Hu-1 libraries were generated in-house with a PCR-based approach, with an average of 2.7 mutations per variant (<italic>
<xref ref-type="bibr" rid="R25">25</xref>
</italic>). Because there were often multiple mutations per variant for the Wuhan-Hu-1 libraries, global epistasis modeling was used to deconvolve the effects of single amino-acid mutations on antibody binding (<italic>
<xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R37">37</xref>
</italic>), whereas for the B.1.351 libraries, the measurements for single-mutant variants were used directly (occasional variants with multiple mutations were discarded) to calculate antibody escape.</p>
</sec>
<sec id="S20">
<title>Generation of pseudotyped lentiviral particles</title>
<p id="P48">HEK-293T (American Type Culture Collection, CRL-3216) cells were used to generate SARS-CoV-2 spike-pseudotyped lentiviral particles and 293T-ACE2 cells (Biodefense and Emerging Infectious Research Resources Repository (BEI Resources), NR-52511) were used to titer the SARS-CoV-2 spike-pseudotyped lentiviral particles and to perform neutralization assays (see below).</p>
<p id="P49">For experiments involving D614G spike, we used spike-pseudotyped lentiviral particles that were generated essentially as described in (<italic>
<xref ref-type="bibr" rid="R70">70</xref>
</italic>), using a codon-optimized SARS-CoV-2 spike from Wuhan-Hu-1 strain that contains a 21-amino-acid deletion at the end of the cytoplasmic tail (<italic>
<xref ref-type="bibr" rid="R27">27</xref>
</italic>) and the D614G mutation that is now predominant in human SARS-CoV-2 (<italic>
<xref ref-type="bibr" rid="R30">30</xref>
</italic>). The plasmid encoding this spike, HDM_Spikedelta21_D614G, is available from Addgene (#158762) and BEI Resources (NR-53765), and the full sequence is at (<ext-link ext-link-type="uri" xlink:href="https://www.addgene.org/158762">https://www.addgene.org/158762</ext-link>). Point mutations were introduced into the RBD of this plasmid via site-directed mutagenesis.</p>
<p id="P50">For experiments involving B.1.351 spike, we introduced the following mutations into the HDM_Spikedelta21_D614G plasmid to match the amino acid sequence of EPI_ISL_700420: 80A, D215G, L242-244del, K417N, E484K, N501Y, and A701V. This plasmid map is available online at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/data/plasmid_maps/2957_HDM_Spikedelta21_B.1.351.gb">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/data/plasmid_maps/2957_HDM_Spikedelta21_B.1.351.gb</ext-link>.</p>
<p id="P51">To generate spike-pseudotyped lentiviral particles (<italic>
<xref ref-type="bibr" rid="R70">70</xref>
</italic>), 6e10<sup>5</sup> HEK-293T (ATCC CRL-3216) cells per well were seeded in 6-well plates in 2 mL D10 growth media (Dulbecco’s Modified Eagle Medium with 10% heat-inactivated fetal bovine serum, 2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin). 24 hours later, cells were transfected using BioT transfection reagent (Bioland Scientific) with a Luciferase_IRES_ZsGreen backbone, Gag/Pol lentiviral helper plasmid (BEI Resources NR-52517), and wild-type or mutant SARS-CoV-2 spike plasmids. Media was changed to fresh D10 at 24 hours post-transfection. At ~60 hours post-transfection, viral supernatants were collected, filtered through a 0.45 μm surfactant-free cellulose acetate low protein-binding filter, and stored at −80°C.</p>
</sec>
<sec id="S21">
<title>Titering of pseudotyped lentiviral particles</title>
<p id="P52">Titers of spike-pseudotyped lentiviral particles were determined as described in (<italic>
<xref ref-type="bibr" rid="R70">70</xref>
</italic>) with the following modifications. 100 μL of diluted spike-pseudotyped lentiviral particles was added to 1.25e4 293T-ACE2 cells (BEI Resources NR-52511), grown overnight in 50 μL of D10 growth media in a 96-well black-walled poly-L-lysine coated plate (Greiner Bio-One, 655936). Relative luciferase units (RLU) were measured 65 hours post-infection (Promega Bright-Glo, E2620) in the infection plates with a black back-sticker (Thermo Fisher Scientific, NC9425162) added to minimize background. Titers were first estimated from the average of 8 two-fold serial dilutions of virus starting at 10 μL virus in a total volume of 150 μL, performed in duplicate.</p>
</sec>
<sec id="S22">
<title>Neutralization assays</title>
<p id="P53">293T-ACE2 cells (BEI Resources NR-52511) were seeded at 1.25e4 cells per well in 50 μL D10 in poly-L-lysine coated, black-walled, 96-well plates (Greiner 655930). 24 hours later, pseudotyped lentivirus supernatants were diluted to ~200,000 RLU per well (determined by titering as described above) and incubated with a range of dilutions of plasma for 1 hour at 37 °C. 100 μL of the virus-antibody mixture was then added to cells. At about 50 or ~70 hours post-infection, luciferase activity was measured using the Bright-Glo Luciferase Assay System (Promega, E2610). Fraction infectivity of each plasma antibody-containing well was calculated relative to a no-plasma well inoculated with the same initial viral supernatant in the same row of the plate. We used the neutcurve package (<ext-link ext-link-type="uri" xlink:href="https://jbloomlab.github.io/neutcurve">https://jbloomlab.github.io/neutcurve</ext-link> version0.5.7) to calculate the inhibitory concentration 50% (IC<sub>50</sub>) and the neutralization titer 50% (NT<sub>50</sub>), which is 1/IC<sub>50</sub>, of each plasma against each virus by fitting a Hill curve with the bottom fixed at 0 and the top fixed at 1.</p>
</sec>
<sec id="S23">
<title>Depletion of RBD-binding antibodies from polyclonal sera</title>
<p id="P54">Two rounds of sequential depletion of RBD-binding antibodies were performed for vaccine-elicited sera. Magnetic beads conjugated to the SARS-CoV-2 B.1.351 RBD (ACROBiosystems, MBS-K032) were prepared according to the manufacturer’s protocol. Beads were resuspended in ultrapure water at 1 mg beads/mL and a magnet was used to wash the beads 3 times in phosphate-buffered saline (PBS) with 0.05% bovine serum albumin (BSA). Beads were then resuspended in PBS with 0.05% BSA at 1 mg beads per mL. Beads (manufacturer-reported binding capacity of 10–40 μg/mL anti-RBD antibodies) were incubated with human plasma at a 2:1 ratio beads:plasma, rotating overnight at 4°C or for 2 hours at room temperature. A magnet (MagnaRack Magnetic Separation Rack, Thermo Fisher Scientific, CS15000) was used to separate antibodies that bind RBD from the supernatant, and the supernatant (the post-RBD antibody depletion sample) was removed. A mock depletion (pre-depletion sample) was performed by adding an equivalent volume of PBS + 0.05% BSA and rotating overnight at 4°C or for 2 hours at room temperature. Up to three rounds of depletions were performed to ensure full depletion of RBD-binding antibodies. For the neutralization assays on these plasmas depleted of RBD-binding antibodies, the reported plasma dilution is corrected for the dilution incurred by the depletion process. Note that these assays were performed in 293T cells over-expressing human ACE2, which may underestimate contributions of non-RBD-binding antibodies to viral neutralization (<italic>
<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R60">60</xref>
</italic>).</p>
</sec>
<sec id="S24">
<title>Measurement of plasma binding to RBD or spike by enzyme-linked immunosorbent assay (ELISA)</title>
<p id="P55">The IgG ELISAs for spike protein and RBD were conducted as previously described (<italic>
<xref ref-type="bibr" rid="R71">71</xref>
</italic>). Briefly, ELISA plates were coated with recombinant B.1.351 spike (purified and prepared as described in (<italic>
<xref ref-type="bibr" rid="R71">71</xref>
</italic>)) and RBD (ACROBiosystems, SPD-C52Hp) antigens described in at 2 μg/mL. Five 3-fold serial dilutions of sera beginning at 1:500 were performed in PBS with 0.1% Tween with 1% Carnation nonfat dry milk. Dilution series of the synthetic sera comprised of the anti-RBD antibody REGN10987 (<italic>
<xref ref-type="bibr" rid="R72">72</xref>
</italic>), which binds to both Wuhan-1-like RBD and B.1.351 RBD, and pooled pre-pandemic human serum from 2017-2018 (Gemini Biosciences; nos. 100–110, lot H86W03J; pooled from 75 donors) were performed such that the anti-spike antibody was present at a highest concentration of 0.25 μg/mL. REGN10987 was recombinantly produced by Genscript. The REGN10987 is the same as that used in (<italic>
<xref ref-type="bibr" rid="R73">73</xref>
</italic>). Pre-pandemic serum alone, without anti-RBD antibody depletion, was used as a negative control, averaged over 2 replicates. Secondary labeling was performed with goat anti-human IgG-Fc horseradish peroxidase (HRP) (1:3000, Bethyl Labs, A80-104P). Antibody binding was detected with TMB/E HRP substrate (Millipore Sigma, ES001) and 1 N HCl was used to stop the reaction. OD<sub>450</sub> was read on a Tecan infinite M1000Pro plate reader.</p>
</sec>
<sec id="S25">
<title>Data visualization</title>
<p id="P56">The static logo plot visualizations of the escape maps in the paper figures were created using the dmslogo package (<ext-link ext-link-type="uri" xlink:href="https://jbloomlab.github.io/dmslogo">https://jbloomlab.github.io/dmslogo</ext-link>, version 0.6.2) and in all cases the height of each letter indicates the escape fraction for that amino-acid mutation calculated as described above. For each sample, the y-axis is scaled to be the greatest of (a) the maximum site-wise escape metric observed for that sample, (b) 20x the median site-wise escape fraction observed across all sites for that plasma, or (c) an absolute value of 1.0 (to appropriately scale samples that are not noisy but for which no mutation has a strong effect on antibody binding). Sites K417, L452, S477, T478, E484, and N501 have been added to logo plots due to their frequencies among circulating viruses. The code that generates these logo plot visualizations is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/results/summary/escape_profiles.md">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/results/summary/escape_profiles.md</ext-link>. In many of the visualizations, the RBD sites are categorized by epitope region (<italic>
<xref ref-type="bibr" rid="R23">23</xref>
</italic>) and colored accordingly. We define the class 1 epitope as residues 403+405+406+417+420+421+453+455–460+473–476+486+487+489+504, the class 2 epitope as residues 472+483–485+490–494, the class 3 epitope to be residues 345+346+437–452+496+498–501, and the class 4 epitope as residues 365–372+378+382–386.</p>
<p id="P57">For the static structural visualizations in the paper figures, the RBD surface (PDB 6M0J) was colored by the site-wise escape metric at each site, with white indicating no escape and red scaled to be the same maximum used to scale the y-axis in the logo plot escape maps, determined as described above. We created interactive structure-based visualizations of the escape maps using dms-view (<italic>
<xref ref-type="bibr" rid="R74">74</xref>
</italic>) that are available at <ext-link ext-link-type="uri" xlink:href="https://jbloomlab.github.io/SARS-CoV-2-RBD_B.1.351/">https://jbloomlab.github.io/SARS-CoV-2-RBD_B.1.351/</ext-link>. The logo plots in these escape maps can be colored according to the deep mutational scanning measurements of how mutations affect ACE2 binding or RBD expression as described above.</p>
</sec>
<sec id="S26">
<title>Statistical Analysis</title>
<p id="P58">The percent of neutralizing activity of early-2020 and B.1.351-convalescent plasmas due to RBD-binding antibodies is plotted with the plotnine python package, version 0.8.0 (<ext-link ext-link-type="uri" xlink:href="https://plotnine.readthedocs.io/en/stable/index.html">https://plotnine.readthedocs.io/en/stable/index.html</ext-link>), shown as a Tukey boxplot (middle line indicating median, box limits indicating interquartile range) with individual measurements overlaid as points. P-values are from a log-rank test accounting for censoring, calculated with the lifelines python package, version 0.25.10 (<ext-link ext-link-type="uri" xlink:href="https://lifelines.readthedocs.io/en/latest/">https://lifelines.readthedocs.io/en/latest/</ext-link>).</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary File 1</label>
<media xlink:href="EMS136910-supplement-Supplementary_File_1.csv" mimetype="text" mime-subtype="csv; charset=utf-8" id="N67292" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>Supplementary File 2</label>
<media xlink:href="EMS136910-supplement-Supplementary_File_2.csv" mimetype="text" mime-subtype="csv; charset=utf-8" id="N67301" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD3">
<label>Supplementary File 3</label>
<media xlink:href="EMS136910-supplement-Supplementary_File_3.csv" mimetype="text" mime-subtype="csv; charset=utf-8" id="N67310" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD4">
<label>Supplementary File 4</label>
<media xlink:href="EMS136910-supplement-Supplementary_File_4.csv" mimetype="text" mime-subtype="csv; charset=utf-8" id="N67319" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD5">
<label>Supplementary File 5</label>
<media xlink:href="EMS136910-supplement-Supplementary_File_5.csv" mimetype="text" mime-subtype="csv; charset=utf-8" id="N67328" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD6">
<label>Supplementary Figures</label>
<media xlink:href="EMS136910-supplement-Supplementary_Figures.pdf" mimetype="application" mime-subtype="pdf" id="N67337" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S27">
<title>Acknowledgements</title>
<p>We thank Cathy Lin for administrative support; Dolores Covarrubias, Andy Marty, the Genomics and Flow Cytometry core facilities at the Fred Hutchinson Cancer Research Center, and Katy Munson at the University of Washington PacBio Sequencing Services for experimental support. We also thank all study participants for their generous participation and contribution to this work.</p>
<sec id="S28">
<title>Funding</title>
<p>This project has been funded in part with federal funds from the NIAID/NIH under contract numbers HHSN272201400006C and 75N93021C00015. This work was supported by grants from the NIAID / NIH (R01AI141707 to J.D.B., and T32AI083203 to A.J.G.., DP1AI158186 and HHSN272201700059C to D.V.), a Pew Biomedical Scholars Award (D.V.), an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (D.V.), and the Gates Foundation (INV-004949 to J.D.B, INV-016575 to H.Y.C. OPP1156262 to D.V., and INV-018944 to A.S.). The Scientific Computing Infrastructure at Fred Hutch is funded by ORIP grant S10OD028685. T.N.S. is a Howard Hughes Medical Institute Fellow of the Damon Runyon Cancer Research Foundation (DRG-2381-19). J.D.B. is an Investigator of the Howard Hughes Medical Institute. H.Y.C. is also funded by an Emergent Ventures Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the US government or the other sponsors.</p>
</sec>
</ack>
<sec id="S29" sec-type="data-availability">
<title>Data and materials availability</title>
<p id="P59">All data associated with this study are in the paper or supplementary materials. The SARS-CoV-2 RBD mutant libraries and unmutated parental plasmid are available upon request with completion of an MTA. The plasmid encoding the SARS-CoV-2 spike gene used to generate pseudotyped lentiviral particles, HDM_Spikedelta21_D614G, is available from Addgene (#158762) and BEI Resources (NR-53765). The HDM_Spikedelta21_B.1.351 plasmid is available upon request. Further information and requests for reagents and resources should be directed to and will be fulfilled by Jesse Bloom (<email>jbloom@fredhutch.org</email>) upon completion of a materials transfer agreement. The complete code for the full computational data analysis pipeline of the mapping experiments is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351</ext-link>. The escape fraction measured for each mutation in <xref ref-type="supplementary-material" rid="SD3">data file S3</xref> and also at <ext-link ext-link-type="uri" xlink:href="https://github.com/ibloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/results/supp_data/B1351_raw_data.csv">https://github.com/ibloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/results/supp_data/B1351_raw_data.csv</ext-link>. All raw sequencing data are available on the NCBI Short Read Archive at BioProject PRJNA770094, BioSample SAMN22208699, SAMN22208700. The neutralization titers of vaccine- and infection-elicited sera against the tested RBD point mutants is at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/experimental_data/results/neut_titers/neut_titers.csv">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/experimental_data/results/neut_titers/neut_titers.csv</ext-link>.</p>
</sec>
<fn-group>
<fn fn-type="con" id="FN2">
<p>
<bold>Author contributions:</bold>
</p>
<p id="P60">A.J.G., A.S., and J.D.B. conceptualized and designed the study. A.J.G. and T.N.S. developed the yeast-display deep mutational scanning antibody-escape mapping method. A.J.G. performed the serum-escape mapping. T.N.S. and A.J.G. performed the deep mutational scanning experiments for ACE2 binding and RBD expression. A.N.L. designed the B.1.351 spike plasmid. R.T.E. and A.N.L. cloned spike point mutants and generated pseudotyped lentiviral particles. R.T.E. and A.J.G. performed pseudotyped neutralization assays. A.J.G., T.N.S., and J.D.B. wrote the code and performed the formal analysis. H.Y.C., J.K.L., K.K., F.K., S.C., and A.S. collected and provided the convalescent plasma samples. J.E.B., D.C., and D.V. provided the B.1.351 spike and RBD for ELISA experiments. A.J.G. and J.D.B. wrote the original draft and all authors reviewed and edited the manuscript.</p>
</fn>
<fn id="FN3" fn-type="conflict">
<p id="P61">
<bold>Competing interests:</bold>
</p>
<p id="P62">J.D.B. consults for Moderna and Flagship Labs 77 on topics related to viral evolution, and has the potential to receive a share of IP revenue as an inventor on a Fred Hutch optioned technology/patent (application WO2020006494) related to deep mutational scanning of viral proteins. H.Y.C. is a consultant for Merck, Pfizer, Ellume, and the Bill and Melinda Gates Foundation and has received support from Cepheid and Sanofi-Pasteur. D.V. is named as an inventor on a patent application filed by the University of Washington related to SARS-CoV-2 vaccines and has received an unrelated sponsored research agreement from Vir Biotechnology Inc. D.C. is an employee of and may hold shares in Vir Biotechnology. The other authors declare no competing interests.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gazy</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hwa</surname>
<given-names>S-H</given-names>
</name>
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lustig</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Giandhari</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pillay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Naidoo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Karim</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<collab>Network for Genomic Surveillance in South Africa, COMMIT-KZN Team</collab>
<article-title>Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma</article-title>
<source>Nature</source>
<year>2021</year>
<volume>593</volume>
<fpage>142</fpage>
<lpage>146</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wibmer</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Ayres</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hermanus</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Madzivhandila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kgagudi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Oosthuysen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lambson</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vermeulen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van der Berg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rossouw</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma</article-title>
<source>Nat Med</source>
<year>2021</year>
<volume>27</volume>
<fpage>622</fpage>
<lpage>625</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Garcia-Knight</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Khalid</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Servellita</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Sotomayor-González</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Glasner</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Reyes</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Gliwa</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>NP</given-names>
</name>
<etal/>
</person-group>
<article-title>Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant</article-title>
<source>Cell</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2021.04.025</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ginn</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Supasa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tuekprakhon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nutalai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Menteer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Duyvesteyn</surname>
<given-names>HME</given-names>
</name>
<etal/>
</person-group>
<article-title>Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>4220</fpage>
<lpage>4236</lpage>
<elocation-id>e13</elocation-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Annavajhala</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Mohri</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zucker</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gomez-Simmonds</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Tagliavia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York</article-title>
<source>Nature</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1038/s41586-021-03908-2</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCarthy</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Rennick</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Nambulli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Robinson-McCarthy</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Bain</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Haidar</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Duprex</surname>
<given-names>WP</given-names>
</name>
</person-group>
<article-title>Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape</article-title>
<source>Science</source>
<year>2021</year>
<volume>371</volume>
<fpage>1139</fpage>
<lpage>1142</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>VanBlargan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Errico</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Suryadevara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies</article-title>
<source>Nat Med</source>
<year>2021</year>
<volume>27</volume>
<fpage>717</fpage>
<lpage>726</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Iketani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kwong</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>BS</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7</article-title>
<source>Nature</source>
<year>2021</year>
<volume>593</volume>
<fpage>130</fpage>
<lpage>135</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCallum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lempp</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zepeda</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2332</fpage>
<lpage>2347</lpage>
<elocation-id>e16</elocation-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCallum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bassi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Di Iulio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>M-J</given-names>
</name>
<name>
<surname>Silacci-Fregni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Saliba</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sprouse</surname>
<given-names>KR</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 immune evasion by the B.1.427/B.1.429variant of concern</article-title>
<source>Science</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1126/science.abi7994</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collier</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>IATM</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Datir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Kemp S</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Bassi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fregni</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>The CITIID-NIHRBioResource COVID-19 Collaboration, The COVID-19 Genomics UK (COG-UK) consortium, Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies</article-title>
<source>Nature</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1038/s41586-021-03412-7</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCallum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Sprouse</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>deMarco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Franko</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tilles</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Logue</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Miranda</surname>
<given-names>MC</given-names>
</name>
<etal/>
</person-group>
<article-title>Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants</article-title>
<source>bioRxivorg</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1101/2021.08.11.455956</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mlcochova</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dhar</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Papa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>IATM</given-names>
</name>
<name>
<surname>Datir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Albecka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<collab>Indian SARS-CoV-2Genomics Consortium (INSACOG), Genotype to Phenotype Japan (G2P-Japan)Consortium, CITIID-NIHR BioResource COVID-19 Collaboration</collab>
<article-title>SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion</article-title>
<source>Nature</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1038/s41586-021-03944-y</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Morishita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nobusawa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tonegawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sakae</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Amino-acid change on the antigenic region B1 of H3 haemagglutinin may be a trigger forthe emergence of drift strain of influenza A virus</article-title>
<source>Epidemiol Infect</source>
<year>2004</year>
<volume>132</volume>
<fpage>399</fpage>
<lpage>406</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nobusawa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Omagari</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Reactivity of human convalescentsera with influenza virus hemagglutinin protein mutants at antigenic site A</article-title>
<source>Microbiol Immunol</source>
<year>2012</year>
<volume>56</volume>
<fpage>99</fpage>
<lpage>106</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>K</given-names>
</name>
<name>
<surname>West</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>James</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Air</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses</article-title>
<source>PLoS One</source>
<year>2012</year>
<volume>7</volume>
<elocation-id>e41895</elocation-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Giovanetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iranzadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fonseca</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giandhari</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Doolabh</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pillay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>San</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Msomi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mlisana</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>Detection of aSARS-CoV-2 variant of concern in South Africa</article-title>
<source>Nature</source>
<year>2021</year>
<volume>592</volume>
<fpage>438</fpage>
<lpage>443</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Hodcroft</surname>
<given-names>EB</given-names>
</name>
</person-group>
<source>CoVariants: SARS-CoV-2 Mutations and Variants of Interest</source>
<year>2021</year>
<comment>available at <ext-link ext-link-type="uri" xlink:href="https://covariants.org/">https://covariants.org/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vogels</surname>
<given-names>CBF</given-names>
</name>
<name>
<surname>Yildirim</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rothman</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Monteiro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gelhausen</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tabachikova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muenker</surname>
<given-names>MC</given-names>
</name>
<etal/>
</person-group>
<article-title>YaleSARS-CoV-2 Genomic Surveillance Initiative, Impact of circulating SARS-CoV-2 variants onm RNA vaccine-induced immunity in uninfected and previously infected individuals</article-title>
<source>bioRxiv</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1101/2021.07.14.21260307</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Weisblum</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schaefer-Babajew</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cipolla</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>TY</given-names>
</name>
<etal/>
</person-group>
<article-title>mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants</article-title>
<source>Nature</source>
<year>2021</year>
<volume>592</volume>
<fpage>616</fpage>
<lpage>622</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Veyer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Baidaliuk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Staropoli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Guivel-Benhassine</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rajah</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Planchais</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Porrot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Robillard</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Puech</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Prot</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization</article-title>
<source>Nature</source>
<year>2021</year>
<volume>596</volume>
<fpage>276</fpage>
<lpage>280</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moyo-Gwete</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Madzivhandila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Makhado</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ayres</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mhlanga</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oosthuysen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lambson</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Kgagudi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Iranzadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Doolabh</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2(B.1.351)</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<elocation-id>2021.03.06.434193</elocation-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Jette</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Abernathy</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Dam</surname>
<given-names>K-MA</given-names>
</name>
<name>
<surname>Esswein</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Gristick</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Malyutin</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Sharaf</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Huey-Tubman</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>Robbiani</surname>
<given-names>DF</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies</article-title>
<source>Nature</source>
<year>2020</year>
<volume>588</volume>
<fpage>682</fpage>
<lpage>687</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Weisblum</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Caskey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Agudelo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>4196</elocation-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>King</surname>
<given-names>NP</given-names>
</name>
<etal/>
</person-group>
<article-title>Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>1295</fpage>
<lpage>1310</lpage>
<elocation-id>e20</elocation-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2</article-title>
<source>Elife</source>
<year>2021</year>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.69091</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Wilcox</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Logue</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Shuey</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Casto</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Fiala</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wrenn</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pettie</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection</article-title>
<source>J Infect Dis</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1093/infdis/jiaa618</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Loes</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Malone</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domainthat affect recognition by polyclonal human plasma antibodies</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<volume>29</volume>
<fpage>463</fpage>
<lpage>476</lpage>
<elocation-id>e6</elocation-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>NF</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Frazar</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Roychoudhury</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Moncla</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Pelle</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ryke</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shrestha</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State</article-title>
<source>Sci Transl Med</source>
<year>2021</year>
<fpage>13</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.abf0202</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korber</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Gnanakaran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Theiler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abfalterer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hengartner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Giorgi</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hastie</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group>
<collab>Sheffield COVID-19 Genomics Group</collab>
<article-title>Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>812</fpage>
<lpage>827</lpage>
<elocation-id>e19</elocation-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piccoli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Czudnochowski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silacci-Fregni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Acton</surname>
<given-names>OJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>1024</fpage>
<lpage>1042</lpage>
<elocation-id>e21</elocation-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ginn</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Duyvesteyn</surname>
<given-names>HME</given-names>
</name>
<name>
<surname>Supasa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Menteer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>The antigenic anatomy of SARS-CoV-2 receptor binding domain</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2183</fpage>
<lpage>2200</lpage>
<elocation-id>e22</elocation-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>JF-W</given-names>
</name>
<name>
<surname>Sahi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Figueroa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>XV</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>450</fpage>
<lpage>456</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voss</surname>
<given-names>WN</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Delidakis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Javanmardi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Horton</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Barteoka</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Paresi</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Tanno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>C-W</given-names>
</name>
<etal/>
</person-group>
<article-title>Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBDs pike epitopes</article-title>
<source>Science</source>
<year>2021</year>
<volume>372</volume>
<fpage>1108</fpage>
<lpage>1112</lpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suryadevara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shrihari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>VanBlargan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Nargi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Fouch</surname>
<given-names>ME</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2316</fpage>
<lpage>2331</lpage>
<elocation-id>e15</elocation-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lempp</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Soriaga</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Montiel-Ruiz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Benigni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Noack</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies</article-title>
<source>Nature</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1038/s41586-021-03925-1</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Loes</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Huddleston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<etal/>
</person-group>
<article-title>Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-BindingDomain that Escape Antibody Recognition</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<volume>29</volume>
<fpage>44</fpage>
<lpage>57</lpage>
<elocation-id>e9</elocation-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Loes</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Gentles</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Malone</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Antibodies elicited by mRNA-1273 vaccination bind more broadly to thereceptor binding domain than do those from SARS-CoV-2 infection</article-title>
<source>Sci Transl Med</source>
<year>2021</year>
<volume>13</volume>
<pub-id pub-id-type="doi">10.1126/scitranslmed.abi9915</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Nkolola</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reidy</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Trivette</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nargi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group>
<article-title>Potently neutralizing and protective human antibodies against SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>443</fpage>
<lpage>449</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jaconi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Culap</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title>
<source>Nature</source>
<year>2020</year>
<volume>583</volume>
<fpage>290</fpage>
<lpage>295</lpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fontes-Garfias</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2vaccine-elicited sera</article-title>
<source>Nat Med</source>
<year>2021</year>
<volume>27</volume>
<fpage>620</fpage>
<lpage>621</lpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weisblum</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>DaSilva</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Poston</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rutkowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>H-H</given-names>
</name>
<name>
<surname>Michailidis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Escape from neutralizing antibodiesby SARS-CoV-2 spike protein variants</article-title>
<source>Elife</source>
<year>2020</year>
<fpage>9</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.61312</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Supasa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Menteer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ginn</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Duyvesteyn</surname>
<given-names>HME</given-names>
</name>
<name>
<surname>Tuekprakhon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nutalai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera</article-title>
<source>Cell</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2021.02.037</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>VanBlargan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Bloyet</surname>
<given-names>L-M</given-names>
</name>
<name>
<surname>Rothlauf</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Stumpf</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Errico</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Theel</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Liebeskind</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Alford</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<elocation-id>2020.11.06.372037</elocation-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandbulte</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Westgeest</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Klimov</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Fouchier</surname>
<given-names>RAM</given-names>
</name>
<name>
<surname>Eichelberger</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2011</year>
<volume>108</volume>
<fpage>20748</fpage>
<lpage>20753</lpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hancock</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Veguilla</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>DeVos</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Gargiullo</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Brammer</surname>
<given-names>TL</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus</article-title>
<source>N Engl J Med</source>
<year>2009</year>
<volume>361</volume>
<fpage>1945</fpage>
<lpage>1952</lpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Worobey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>G-Z</given-names>
</name>
<name>
<surname>Rambaut</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2014</year>
<volume>111</volume>
<fpage>8107</fpage>
<lpage>8112</lpage>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gagnon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Acosta</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hallman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bourbeau</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dillon</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Ouellette</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Earn</surname>
<given-names>DJD</given-names>
</name>
<name>
<surname>Herring</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Inwood</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Madrenas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Pandemic Paradox: Early Life H2N2 Pandemic Influenza Infection Enhanced Susceptibility to Death during the 2009 H1N1 Pandemic</article-title>
<source>MBio</source>
<year>2018</year>
<fpage>9</fpage>
<pub-id pub-id-type="doi">10.1128/mBio.02091-17</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Hensley</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>IA</given-names>
</name>
</person-group>
<article-title>Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal VaccineImmunogens</article-title>
<source>J Infect Dis</source>
<year>2019</year>
<volume>219</volume>
<fpage>S38</fpage>
<lpage>S45</lpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016</article-title>
<source>Cell Rep Med</source>
<year>2021</year>
<volume>2</volume>
<elocation-id>100255</elocation-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>JCC</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tokuyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jankovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schaefer-Babajew</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Cipolla</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Evolution of antibody immunity to SARS-CoV-2</article-title>
<source>Nature</source>
<year>2021</year>
<volume>591</volume>
<fpage>639</fpage>
<lpage>644</lpage>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rapp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Reddem</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cerutti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Katsamba</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bimela</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Bahna</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Mannepalli</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group>
<article-title>Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class</article-title>
<source>Cell Rep</source>
<year>2021</year>
<volume>35</volume>
<elocation-id>108950</elocation-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbiani</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>JCC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Agudelo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Gazumyan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hägglöf</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>437</fpage>
<lpage>442</lpage>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Momsen Reincke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kornau</surname>
<given-names>H-C</given-names>
</name>
<name>
<surname>Corman</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>van Hoof</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sánchez-Sendin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ramberger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tien</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.09.30.462420</elocation-id>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>W-T</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Callaghan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Musharrafieh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beutler</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Melo</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.07.05.451222</elocation-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faulkner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Margaritis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Paraskevopoulou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Houlihan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bolland</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Warchal</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains</article-title>
<source>Elife</source>
<year>2021</year>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.69317</pub-id>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Goldhill</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peacock</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Frise</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Goonawardane</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Baillon</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kugathasan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>McKay</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Hassard</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by areplicative advantage in primary airway cells or antibody escape</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.02.24.432576</elocation-id>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laurie</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sunshine</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Pilarowski</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zorn</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Rubio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bravo</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<source>Exposures to different SARS-CoV-2 spike variants elicit neutralizing antibody responses with differential specificity towards established and emerging strains</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1101/2021.09.08.21263095</pub-id>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Karim</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lustig</surname>
<given-names>G</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Hermanus</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Snyman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hwa</surname>
<given-names>S-H</given-names>
</name>
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>COMMIT-KZN Team, Divergence of delta and beta variants and SARS-CoV-2 evolved in prolongedinfection into distinct serological phenotypes</article-title>
<source>bioRxiv</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1101/2021.09.14.21263564</pub-id>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>650</fpage>
<lpage>655</lpage>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kistler</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Huddleston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2</article-title>
<source>bioRxiv</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1101/2021.09.11.459844</pub-id>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eguia</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Stevens-Ayers</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kelnhofer-Millevolte</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Greninger</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Englund</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Boeckh</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>A human coronavirus evolves antigenically to escape antibody immunity</article-title>
<source>PLoS Pathog</source>
<year>2021</year>
<volume>17</volume>
<elocation-id>e1009453</elocation-id>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kistler</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229E</article-title>
<source>Elife</source>
<year>2021</year>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.64509</pub-id>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francis</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>On the Doctrine of Original Antigenic Sin</article-title>
<source>Proc Am Philos Soc</source>
<year>1960</year>
<volume>104</volume>
<fpage>572</fpage>
<lpage>578</lpage>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Webster</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Arbor</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>Journal of Experimental Medicine</source>
<year>1966</year>
<publisher-name>Citeseer</publisher-name>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.273.1066">http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.273.1066</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Zepeda</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>ACE2 bindingis an ancestral and evolvable trait of sarbecoviruses</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.07.17.452804</elocation-id>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wente</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Shusta</surname>
<given-names>EV</given-names>
</name>
</person-group>
<article-title>A novel high-throughput screen reveals yeast genes that increase secretion of heterologous proteins</article-title>
<source>Appl Environ Microbiol</source>
<year>2007</year>
<volume>73</volume>
<fpage>1189</fpage>
<lpage>1198</lpage>
</element-citation>
</ref>
<ref id="R68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giete</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Schiestl</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Large-scale high-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method</article-title>
<source>Nat Protoc</source>
<year>2007</year>
<volume>2</volume>
<fpage>38</fpage>
<lpage>41</lpage>
</element-citation>
</ref>
<ref id="R69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>alignparse: A Python package for parsing complex features from high-throughput long-read sequencing</article-title>
<source>J Open Source Softw</source>
<year>2019</year>
<fpage>4</fpage>
<pub-id pub-id-type="doi">10.21105/joss.01915</pub-id>
</element-citation>
</ref>
<ref id="R70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Loes</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Malone</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pettie</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays</article-title>
<source>Viruses</source>
<year>2020</year>
<fpage>12</fpage>
<pub-id pub-id-type="doi">10.3390/v12050513</pub-id>
</element-citation>
</ref>
<ref id="R71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Lacombe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Amanat</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pettie</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>4378</elocation-id>
</element-citation>
</ref>
<ref id="R72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pascal</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wloga</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fulton</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Koon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group>
<article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1010</fpage>
<lpage>1014</lpage>
</element-citation>
</ref>
<ref id="R73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Addetia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hannon</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Prospective mapping of viral mutations that escape antibodies used to treat COVID-19</article-title>
<source>Science</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1126/science.abf9302</pub-id>
</element-citation>
</ref>
<ref id="R74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hilton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huddleston$</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>A</given-names>
</name>
<name>
<surname>North</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>dms-view: Interactive visualization tool for deep mutational scanning data</article-title>
<source>J Open Source Softw</source>
<year>2020</year>
<volume>5</volume>
<elocation-id>2353</elocation-id>
</element-citation>
</ref>
<ref id="R75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrobel</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Benton</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Roustan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Skehel</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Gamblin</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects</article-title>
<source>Nat Struct Mol Biol</source>
<year>2020</year>
<volume>27</volume>
<fpage>763</fpage>
<lpage>767</lpage>
</element-citation>
</ref>
<ref id="R76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>
<source>Nature</source>
<year>2020</year>
<volume>581</volume>
<fpage>215</fpage>
<lpage>220</lpage>
</element-citation>
</ref>
<ref id="R77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brouwer</surname>
<given-names>PJM</given-names>
</name>
<name>
<surname>Caniels</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>van der Straten</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Snitselaar</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Aldon</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bangaru</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Okba</surname>
<given-names>NMA</given-names>
</name>
<name>
<surname>Claireaux</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kerster</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bentlage</surname>
<given-names>AEH</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>643</fpage>
<lpage>650</lpage>
</element-citation>
</ref>
<ref id="R78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seydoux</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Homad</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>MacCamy</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Parks</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Hurlburt</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Jennewein</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Akins</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Stuart</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Y-H</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Whaley</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group>
<article-title>Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation</article-title>
<source>Immunity</source>
<year>2020</year>
<volume>53</volume>
<fpage>98</fpage>
<lpage>105</lpage>
<elocation-id>e5</elocation-id>
</element-citation>
</ref>
<ref id="R79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Beutler</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>A</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W-T</given-names>
</name>
<name>
<surname>Limbo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Woehl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>956</fpage>
<lpage>963</lpage>
</element-citation>
</ref>
<ref id="R80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>Human neutralizing antibodies elicited by SARS-CoV-2 infection</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>115</fpage>
<lpage>119</lpage>
</element-citation>
</ref>
<ref id="R81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elbe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Buckland-Merrett</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Data, disease and diplomacy: GISAID’s innovative contribution to global health</article-title>
<source>Glob Chall</source>
<year>2017</year>
<volume>1</volume>
<fpage>33</fpage>
<lpage>46</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<title>B.1.351 spike mutations.</title>
<p>
<bold>(A,B)</bold> Mutations in the B.1.351 spike relative to Wuhan-Hu-1 (<italic>
<xref ref-type="bibr" rid="R17">17</xref>
</italic>). L18F is only present in some B.1.351 isolates. Visualization generated by <ext-link ext-link-type="uri" xlink:href="https://covdb.stanford.edu/sierra/sars2/by-paherns/">https://covdb.stanford.edu/sierra/sars2/by-paherns/</ext-link>. <bold>(C)</bold> Sites where mutations occur in the spike ectodomain are highlighted in blue on the Wuhan-Hu-1 one-RBD open spike trimer (left, PDB 6ZGG)(<italic>
<xref ref-type="bibr" rid="R75">75</xref>
</italic>) or RBD (right) (PDB 6M0J)(<italic>
<xref ref-type="bibr" rid="R76">76</xref>
</italic>). The surface of one spike monomer is shown; the other two protomers are transparent.</p>
</caption>
<graphic xlink:href="EMS136910-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<title>The neutralizing activity of plasma antibodies elicited by B.1.351 infection is heavily focused on the RBD.</title>
<p>
<bold>(A)</bold> The neutralizing titer (NT50) of plasmas from B.1.351-infected individuals against B.1.351 spike-pseudotyped lentiviral particles, following mock depletion or depletion of B.1.351 RBD-binding antibodies. <bold>(B)</bold> Comparison of neutralization titer following mock depletion or depletion of B.1.351 RBD-binding antibodies for early 2020 (n=17) (<italic>
<xref ref-type="bibr" rid="R28">28</xref>
</italic>) and B.1.351 convalescent plasmas (n=9). The pink dashed line in A,B indicates the limit of detection (NT50 of 25 for B.1.351 plasmas, and 20 for early 2020 plasmas). <bold>(C)</bold> Percent loss of neutralization after removal of RBD-binding antibodies for early 2020 and B.1.351 convalescent plasmas. The difference is not significant (Cox proportional-hazards test, accounting for censoring, p = 0.12). Experiments with B.1.351 infection-elicited plasmas were performed with B.1.351 RBD proteins and spike-pseudotyped lentiviruses, and experiments with early 2020 plasmas were performed with Wuhan-Hu-1 RBD proteins and D614G spike-pseudotyped lentiviruses. The data for the early 2020 viruses are reprinted from (<italic>
<xref ref-type="bibr" rid="R28">28</xref>
</italic>). Neutralization titers are in <xref ref-type="supplementary-material" rid="SD1">data file S1</xref> and at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/experimental_data/results/rbd_depletion_neuts/RBD_depletion_NT50_b1351_haarvi.csv">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/experimental_data/results/rbd_depletion_neuts/RBD_depletion_NT50_b1351_haarvi.csv</ext-link>. Full neutralization curves for the B.1.351 plasmas are in <xref ref-type="supplementary-material" rid="SD6">fig. S1</xref>, and the full curves for the early 2020 plasmas are shown in the supplement of (<italic>
<xref ref-type="bibr" rid="R28">28</xref>
</italic>).</p>
</caption>
<graphic xlink:href="EMS136910-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<title>Complete maps of mutations in the B.1.351 RBD that reduce binding by B.1.351 convalescent plasmas.</title>
<p>
<bold>(A)</bold> The Wuhan-Hu-1 RBD (PDB 6M0J) colored by antibody epitope (<italic>
<xref ref-type="bibr" rid="R23">23</xref>
</italic>). The three sites where mutations distinguish the Wuhan-Hu-1 and B.1.351 RBDs are labeled. ACE2 is shown as a gray ribbon diagram. <bold>(B)</bold> Escape maps for B.1.351 convalescent plasmas. The line plots at left indicate the sum of effects of all mutations at each RBD site on plasma antibody binding, with larger values indicating more escape. The logo plots at right show key sites (highlighted in purple on the line plot x-axes). The height of each letter is that mutation’s escape fraction; larger letters indicate a greater reduction in binding. For each sample, the y-axis is scaled independently. RBD sites are colored by epitope as in (A). Sites 417, 484, and 501 are labeled with red text on the x-axis. All escape scores are in <xref ref-type="supplementary-material" rid="SD3">data file S3</xref> and at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/results/supp_data/B1351_raw_data.csv">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/results/supp_data/B1351_raw_data.csv</ext-link>. Interactive versions of logo plots and structural visualizations are at <ext-link ext-link-type="uri" xlink:href="https://jbloomlab.github.io/SARS-CoV-2-RBD_B.1.351/">https://jbloomlab.github.io/SARS-CoV-2-RBD_B.1.351/</ext-link>.</p>
</caption>
<graphic xlink:href="EMS136910-f003"/>
</fig>
<fig id="F4" position="float">
<label>Fig. 4</label>
<caption>
<title>Comparison of binding escape mutations between plasmas elicited by infection with B.1.351 versus early 2020 viruses.</title>
<p>
<bold>(A)</bold> The total escape at each site is shown as a light gray line for each plasma in the early 2020 or B.1.351 cohorts. The thicker black line indicates the average for each cohort. Key antibody epitopes are highlighted, colored as in <xref ref-type="fig" rid="F2">Fig. 2A</xref>. <bold>(B)</bold> The total escape at each site averaged across each cohort is mapped to the Wuhan-Hu-1 RBD surface (PDB 6M0J (<italic>
<xref ref-type="bibr" rid="R76">76</xref>
</italic>)), with sites colored from white to red, with white indicating no escape, and red being the site with the most escape. Interactive versions of logo plots and structural visualizations are at <ext-link ext-link-type="uri" xlink:href="https://jbloomlab.github.io/SARS-CoV-2-RBD_B.1.351/">https://jbloomlab.github.io/SARS-CoV-2-RBD_B.1.351/</ext-link>. The early 2020 escape-mapping data in this figure were originally published in (<italic>
<xref ref-type="bibr" rid="R28">28</xref>
</italic>) and are reanalyzed here. The full escape maps for the early 2020 samples are shown in <xref ref-type="supplementary-material" rid="SD6">Fig. S4</xref> and the full escape maps for the B.1.351 samples are shown in <xref ref-type="fig" rid="F3">Fig. 3</xref>.</p>
</caption>
<graphic xlink:href="EMS136910-f004"/>
</fig>
<fig id="F5" position="float">
<label>Fig. 5</label>
<caption>
<title>Some mutations have different effects on neutralization by B.1.351 and early 2020 plasmas.</title>
<p>Plasmas from B.1.351- or early 2020-convalescent individuals were tested for neutralization of wildtype B.1.351 or D614G spike-pseudotyped lentiviral particles, respectively, and against the indicated point mutants in their respective parental backgrounds. The y-axis indicates the fold-change in neutralization caused by the mutations, with larger values indicating less neutralization. Each point is the average of two technical replicates for one individual. The crossbars indicate the group geometric mean. The dashed gray line is at 1 (i.e., mutation causes no change in neutralization). Sites 417, 484, and 501 differ between B.1.351 and early 2020 viruses, and so mutations are tested in each background that changes the identity to that in the other virus (e.g., E484K in early 2020 viruses, and K484E in B.1.351). Full neutralization curves and effects of mutations for each individual are shown in <xref ref-type="supplementary-material" rid="SD6">fig. S5</xref>, and the numerical values and IC50s are given in <xref ref-type="supplementary-material" rid="SD5">data file S5</xref> and at <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/experimental_data/results/neut_titers/neut_titers.csv">https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/experimental_data/results/neut_titers/neut_titers.csv</ext-link>.</p>
</caption>
<graphic xlink:href="EMS136910-f005"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Information on cohorts of individuals infected with early 2020 or B.1.351 viruses</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="center" valign="middle">Infecting Virus</th>
<th align="center" valign="middle">Time Period</th>
<th align="center" valign="middle">Location</th>
<th align="center" valign="middle">Days Post-Symptom Onset</th>
<th align="center" valign="middle">Number of Individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle">Early 2020</td>
<td align="center" valign="middle">Prior to March 15, 2020</td>
<td align="center" valign="middle">Washington State, USA</td>
<td align="center" valign="middle">mean 32 (range 15–61)</td>
<td align="center" valign="middle">17</td>
</tr>
<tr>
<td align="center" valign="middle">B.1.351</td>
<td align="center" valign="middle">Late December 2020 to late January 2021</td>
<td align="center" valign="middle">South Africa</td>
<td align="center" valign="middle">mean 33 (range 27–40)</td>
<td align="center" valign="middle">9</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
